Advertisement
Canada markets closed

  • S&P/TSX

    21,554.86
    -26.44 (-0.12%)
     

  • S&P 500

    5,464.62
    -8.55 (-0.16%)
     

  • DOW

    39,150.33
    +15.53 (+0.04%)
     

  • CAD/USD

    0.7304
    -0.0003 (-0.04%)
     

  • CRUDE OIL

    80.59
    -0.14 (-0.17%)
     

  • Bitcoin CAD

    87,773.45
    -243.40 (-0.28%)
     

  • CMC Crypto 200

    1,321.31
    -39.02 (-2.87%)
     

  • GOLD FUTURES

    2,334.70
    +3.50 (+0.15%)
     

  • RUSSELL 2000

    2,022.03
    +4.64 (+0.23%)
     

  • 10-Yr Bond

    4.2570
    +0.0030 (+0.07%)
     

  • NASDAQ

    17,689.36
    -32.24 (-0.18%)
     

  • VOLATILITY

    13.20
    -0.08 (-0.60%)
     

  • FTSE

    8,237.72
    -34.74 (-0.42%)
     

  • NIKKEI 225

    38,596.47
    -36.53 (-0.09%)
     

  • CAD/EUR

    0.6830
    +0.0009 (+0.13%)
     

Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference

Business Wire
·2 min read

FOSTER CITY, Calif., June 05, 2024--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami on Wednesday, June 12th at 10:00 AM EDT.

Visit the Investors and Media section of Mirum’s corporate website for webcast links and additional information.

About Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid) capsules, and CHENODAL® (chenodiol) tablets.

ADVERTISEMENT

LIVMARLI, an IBAT inhibitor, is approved for the treatment of two rare liver diseases affecting children and adults. It is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the U.S. (three months and older), in Europe (two months and older), and in other regions globally. It is also approved in the U.S. in cholestatic pruritus in PFIC patients five years of age and older. CHOLBAM is FDA-approved for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders in patients who show signs or symptoms or liver disease. CHENODAL has received medical necessity recognition by the FDA to treat patients with cerebrotendinous xanthomatosis (CTX).

Mirum’s late-stage pipeline includes two investigational treatments for debilitating liver diseases. Volixibat, an IBAT inhibitor, is being evaluated in two potentially registrational studies including the Phase 2b VISTAS study for primary sclerosing cholangitis and Phase 2b VANTAGE study for primary biliary cholangitis. Lastly, CHENODAL, has been evaluated in a Phase 3 clinical study, RESTORE, to treat patients with CTX, with positive topline results reported in 2023.

To learn more about Mirum, visit mirumpharma.com and follow Mirum on Facebook, LinkedIn, Instagram and Twitter (X).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240605867852/en/

Contacts

Investor Contact:
Andrew McKibben
ir@mirumpharma.com

Media Contact:
Erin Murphy
media@mirumpharma.com